We are live on ! Find out more

Materialise

MTLS

Market cap $411M

7.18 USD

-0.06

0.83%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

7.18

0.00

0%

1 day

-0.83%

5 days

-16.51%

1 month

-16.12%

3 months

12.01%

6 months

30.78%

Year to date

31.74%

1 year

26.86%

5 years

-72.53%

10 years

5.12%

About: Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.

Employees: 2,556

Technology Software - Application

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Materialise NV (MTLS) Q3 2026 Earnings Call Transcript

Materialise NV ( MTLS ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Jody Burfening Troy Jensen - Cantor Fitzgerald & Co., Research Division Presentation Operator Thank you for standing by, and welcome to the Third Quarter 2026 Materialise NV Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Materialise NV (MTLS) Q3 2026 Earnings Call Transcript

Materialise Q3 Earnings Call Highlights

Materialise NASDAQ: MTLS reported third-quarter 2026 revenue growth led by its medical business, while higher research and development spending and one-time costs weighed on operating profitability. The company reaffirmed its full-year revenue and adjusted EBIT guidance.

Materialise Q3 Earnings Call Highlights

Materialise Reports Third Quarter 2026 Results

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the third quarter ended September 30, 2026. Highlights – Third Quarter 2026 Total revenue increased by 2.1% to 67,670 kEUR for the third quarter of 2026 compared to 66,259 kEUR for the corresponding 2025 period. Excluding last year's revenue for the recen.

Materialise Reports Third Quarter 2026 Results

Materialise NV to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced that it will release financial results for the third quarter ended September 30, 2026 on Wednesday, October 28, 2026 at 2:00 a.m. ET/7:00 a.m. CET. Senior management will hold a conference call to discuss the third quarter 2026 financial results on Wednesday, October 28, 2026 at.

Materialise NV to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026

Materialise: A High-Margin Medical Business Hiding In Plain Sight

Materialise's Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company's value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products.

Materialise: A High-Margin Medical Business Hiding In Plain Sight

Materialise NV (MTLS) Q2 2026 Earnings Call Transcript

Materialise NV (MTLS) Q2 2026 Earnings Call Transcript

Materialise NV (MTLS) Q2 2026 Earnings Call Transcript

Materialise Q2 Earnings Call Highlights

Materialise NASDAQ: MTLS reported second-quarter revenue growth of more than 8% year over year to €70.1 million, driven by double-digit expansion in its Medical segment and continued improvement in profitability. The company raised its full-year adjusted EBIT outlook while maintaining its revenue guidance, despite the anticipated revenue effect of divesting its RapidFit and Eyewear businesses.

Materialise Q2 Earnings Call Highlights

Materialise Reports Second Quarter and Half-Year 2026 Results

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the second quarter and the six months ended June 30, 2026. Highlights – Second Quarter 2026 Total revenue increased by 8.1% to 70,073 kEUR for the second quarter of 2026 compared to 64,831 kEUR for the corresponding 2025 period. Adjusted EBITDA increased.

Materialise Reports Second Quarter and Half-Year 2026 Results

Materialise NV to Report Second Quarter and Half-Year 2026 Earnings on Thursday, August 27, 2026

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced that it will release financial results for the second quarter and the six months ended June 30, 2026 on Thursday, August 27, 2026 at 1:00 a.m. ET/7:00 a.m. CET. Senior management will hold a conference call to discuss the second quarter and the six months ended June 30, 2026 fina.

Materialise NV to Report Second Quarter and Half-Year 2026 Earnings on Thursday, August 27, 2026

Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward

While Materialise's Q1 results were soft, its Medical segment appears to be stabilizing and the software business model transition is nearing completion. Cost discipline and a return to growth should see margins start to consistently move higher, assuming that the macro environment remains stable. Despite the stock moving higher in recent months, a material improvement in performance still isn't priced into the stock.

Materialise: Maturing Transition Should Lead To Stronger Performance Going Forward

See News Rankings

Price charts implemented using Lightweight Charts™